Dailypharm Korea will be available without login access until the end of December 2019.
Membership login access would be required from February 2020 to access more news and website services.
Dailypharm Live Search Close
  • I tried to make the KOEDC 'Social butterfly '
  • by Lee, Jeong-Hwan | translator Choi HeeYoung | May 8, 2020 06:34am
The KOEDC (President Young-mi Yoon)
There are many issues such as profits and courier delivery
 ▲ The KOEDC (President Young-mi Yoon)
“The KOEDC (Korea Orphan & Essential Drug Center) is the place where the government and the public need attention more than any other institution. I wanted to increase the utilization of the public by spreading the awareness to the society that it is a place to supply medicines that are essential for the treatment of incurable patients and that the social supply of essential medicines does not stop. I hope that the government's support for the center's operating budget will increase significantly, and that the capacity to contribute to society will increase rapidly.”

'Inssa (Insider, Social butterfly)', which stands for social and organizational mainstream and friendly person, is a word that seems somewhat distant from the KOEDC.

This is because the KOEDC is dedicated to rare and incurable disease drugs that have a relatively small number of patients or have relatively low social awareness and are less likely to receive social attention.

In a way, the KOEDC seems to have no choice but to support the supply and treatment of remedies for incurable patients who are prone to alienation in society, taking on a task close to Assa (Outsider, not social).

However, President Young-mi Yoon (51, Dongduk University of Pharmacy), who has led the KOECD for the past two years, made efforts to imprint rare disease and the existence of the center by making the center from outsider to insider and beyond to a social bufferfly.

Director Yoon's term for the center ended on the 22nd of last month, but the appointment of the next president has not been completed, and the term has been temporarily extended without a new leader being decided. If the next president is decided, she will be officially retired.

Specifically, Director Yoon is in many ways, including nurturing rare proceeds that have been solidified through 20 years of practice, advancing delivery of orphan drugs through regional centers and base pharmacy projects, and improvement of purchasing treatment hemp oil, led the improvement of the system by communicating with the National Assembly.

This is the background of last year's national audit that raised the center's profits and improved the efficiency of budget support for the MFDS.

Director Yoon suggested that the center's operation would be normalized based on the increase in the budget-to-government support rate for the newly appointed director's main job.

The detailed work is the president's intrinsic competency and authority, but she believes that the lack of budget should not continue to do what the center has to do for the society and patients.

"Unfortunately, in the past two years, we haven't completed the budget support problem for normal operation of the center, the expenditure of money, and the delivery of courier services," she said. In the end, it resulted in the issue of budget support from the MFDS and remained as the next president's homework. ”

"In order to solve the safety issues of biological products that require temperature-controlled shipping and courier delivery with illegality, it is a consignment delivery pilot project, and at the same time, we have worked hard to establish a safe supply process for orphan drugs as a regional base center and base pharmacy. "The system is not complete, but I think this is the way the future center should go," she said.

When asked what led the center to focus on, President Yoon responded, "I wanted to improve the utilization of the center by greatly increasing the interest of the people and society in the center."

The intention is to make the KOEDC that is unfamiliar to the general public a social butterfly .

"To inform the existence of the KOEDC, we needed to innovate in the center's hardware and software as a whole," said Yoon. "We moved the office to the city hall to build facilities such as pharmacies and drug warehouses in the center. This is why we created a process that minimizes supply and demand inconvenience. "

Director Yun suggested that the center should plan to enhance the accessibility and safety of orphan drugs.

In particular, it is said that it is the path for the country and patients to minimize the probability that the center will fall into the supply of orphan drugs even in extreme situations by closely analyzing the current situation in which the domestic supply of orphan drugs in the world is struggling due to the COVID-19 crisis.

"There are more than 20,000 orphan drugs that the center supplies per year. The importance and social needs of orphan drugs are getting bigger every day," she said. Nevertheless, the center still needs to be improved in terms of facilities, management, accounting and operating systems. "It is the KOEDC that can reveal the willingness of the nation to somehow care for the underprivileged," she said.

"We need to constantly monitor which pharmaceutical companies around the world are developing, producing and distributing what kind of pharmaceutical companies in the world and check the distribution line in real time so that we can have the bargaining power to supply domestic patients' drugs," said the Center. It is time to further advance the system to increase social utilization, "she suggested.
“I took the job as a general manager and worked every day, at least once a week, hoping that the KOEDC would be known in the media,” said she. The center faces the challenge of formulating a budget for the MFDS for normal operation. We ask for your continued interest and support to ensure that the Center plays a role in the national health defense frontier.
  • 0
Reader Comment
Anonymity comment Write Operate Rule

댓글 운영방식은

댓글은 실명게재와 익명게재 방식이 있으며, 실명은 이름과 아이디가 노출됩니다. 익명은 필명으로 등록 가능하며, 대댓글은 익명으로 등록 가능합니다.

댓글 노출방식은

댓글 명예자문위원(팜-코니언-필기모양 아이콘)으로 위촉된 데일리팜 회원의 댓글은 ‘게시판형 보기’와 ’펼쳐보기형’ 리스트에서 항상 최상단에 노출됩니다. 새로운 댓글을 올리는 일반회원은 ‘게시판형’과 ‘펼쳐보기형’ 모두 팜코니언 회원이 쓴 댓글의 하단에 실시간 노출됩니다.

댓글의 삭제 기준은

다음의 경우 사전 통보없이 삭제하고 아이디 이용정지 또는 영구 가입제한이 될 수도 있습니다.

  • 저작권·인격권 등 타인의 권리를 침해하는 경우

    상용 프로그램의 등록과 게재, 배포를 안내하는 게시물

    타인 또는 제3자의 저작권 및 기타 권리를 침해한 내용을 담은 게시물

  • 근거 없는 비방·명예를 훼손하는 게시물

    특정 이용자 및 개인에 대한 인신 공격적인 내용의 글 및 직접적인 욕설이 사용된 경우

    특정 지역 및 종교간의 감정대립을 조장하는 내용

    사실 확인이 안된 소문을 유포 시키는 경우

    욕설과 비어, 속어를 담은 내용

    정당법 및 공직선거법, 관계 법령에 저촉되는 경우(선관위 요청 시 즉시 삭제)

    특정 지역이나 단체를 비하하는 경우

    특정인의 명예를 훼손하여 해당인이 삭제를 요청하는 경우

    특정인의 개인정보(주민등록번호, 전화, 상세주소 등)를 무단으로 게시하는 경우

    타인의 ID 혹은 닉네임을 도용하는 경우

  • 게시판 특성상 제한되는 내용

    서비스 주제와 맞지 않는 내용의 글을 게재한 경우

    동일 내용의 연속 게재 및 여러 기사에 중복 게재한 경우

    부분적으로 변경하여 반복 게재하는 경우도 포함

    제목과 관련 없는 내용의 게시물, 제목과 본문이 무관한 경우

    돈벌기 및 직·간접 상업적 목적의 내용이 포함된 게시물

    게시물 읽기 유도 등을 위해 내용과 무관한 제목을 사용한 경우

  • 수사기관 등의 공식적인 요청이 있는 경우

  • 기타사항

    각 서비스의 필요성에 따라 미리 공지한 경우

    기타 법률에 저촉되는 정보 게재를 목적으로 할 경우

    기타 원만한 운영을 위해 운영자가 필요하다고 판단되는 내용

  • 사실 관계 확인 후 삭제

    저작권자로부터 허락받지 않은 내용을 무단 게재, 복제, 배포하는 경우

    타인의 초상권을 침해하거나 개인정보를 유출하는 경우

    당사에 제공한 이용자의 정보가 허위인 경우 (타인의 ID, 비밀번호 도용 등)

  • ※이상의 내용중 일부 사항에 적용될 경우 이용약관 및 관련 법률에 의해 제재를 받으실 수도 있으며, 민·형사상 처벌을 받을 수도 있습니다.

    ※위에 명시되지 않은 내용이더라도 불법적인 내용으로 판단되거나 데일리팜 서비스에 바람직하지 않다고 판단되는 경우는 선 조치 이후 본 관리 기준을 수정 공시하겠습니다.

    ※기타 문의 사항은 데일리팜 운영자에게 연락주십시오. 메일 주소는 dailypharm@dailypharm.com입니다.

recently Agree DisAgree
If you want to see the full article, please JOIN US (click)